Review/People

Heineken

Our regular look at groundbreaking and innovative deals in the primary markets takes in the £400 million unrated Heineken deal, and BP's monster $3.25 billion offering

Roche

An in-depth look at the primary market's most innovative transactions. This month: the $16bn deal from Swiss pharma firm Roche, and Westpac's yen issue

Brushfield Capital CDO

This month's deals are particularly deserving of mention given the recent market turmoil. We highlight Brushfield Capital's CDO, the Dalradian CLO and Gazprom's $1.25bn bond

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here